Combined IFN-γ and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells

Molecular Cancer Therapeutics

Volumn 6, Issue 10, 2007, Pages 2634-2641

  Cetinkaya, Cihan ^a,f   Hultquist, Anne ^b,g   Su, Yingtao ^a,c   Wu, Siqin ^a   Bahram, Fuad ^a   Pålman, Sven ^d   Guzhova, Irina ^a,e   Larsson, Lars Gunnar ^a,c  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e INSTITUTE OF CYTOLOGY   (Russian Federation)

^f AALBORG UNIVERSITY   (Denmark)

^g LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HISTONE H4; MAX PROTEIN; MYC PROTEIN; ORNITHINE DECARBOXYLASE; PROTEIN MAD1; RETINOIC ACID; TELOMERASE REVERSE TRANSCRIPTASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHROMATIN STRUCTURE; CONTROLLED STUDY; DEACETYLATION; DOWN REGULATION; GENE AMPLIFICATION; GENE REPRESSION; GENE TARGETING; HIGH RISK PATIENT; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTO ONCOGENE; TRANSCRIPTION TERMINATION; UPREGULATION;

ACETYLATION; ANTINEOPLASTIC AGENTS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; DIMERIZATION; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; IMMUNOPRECIPITATION; INTERFERON TYPE II; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; ORNITHINE DECARBOXYLASE; PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 35848937783     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0492     Document Type: Article

References (49)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
2. Cohn SL, Tweddle DA. MYCN amplification remains prognostically strong 20 years after its "clinical debut." Eur J Cancer 2004;40:2639-42.
3. Schwab M. MYCN in neuronal tumours. Cancer Lett 2004;204:179-87.
4. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985-95.
5. Strieder V, Lutz W. Regulation of N-myc expression in development and disease. Cancer Lett 2002;180:107-19.
6. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000;16:653-99.
7. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY Complex. Adv Cancer Res 2002;84:81-154.
8. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-45.
9. Baudino TA, Cleveland JL. The Max network gone mad. Mol Cell Biol 2001;21:691-702.
10. Lüscher B. Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene 2001;277:1-14.
11. Zhou ZQ, Hurlin PJ. The interplay between Mad and Myc in proliferation and differentiation. Trends Cell Biol 2001;11:S10-4.
12. Patel JH, Loboda AP, Showe MK, Showe LC, McMahon SB. Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer 2004;4:562-8.
13. Bouchard C, Dittrich O, Kiermaier A, et al. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev 2001;15:2042-7.
14. Xu D, Popov N, Hou M, et al. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A 2001;98:3826-31.
15. Orian A, van Steensel B, Delrow J, et al. Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. Genes Dev 2003;17:1101-14.
16. Wanzel M, Herold S, Eilers M. Transcriptional repression by Myc. Trends Cell Biol 2003;13:146-50.
17. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2:764-76.
18. Edsjo A, Holmquist L, Pahlman S. Neuroblastoma as an experimental model for neuronal differentiation and hypoxia-induced tumor cell dedifferentiation. Semin Cancer Biol 2007;17:248-56.
19. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrowtran splantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
20. Wuarin L, Verity MA, Sidell N. Effects of interferon-γ and its interaction with retinoic acid on human neuroblastoma differentiation. Int J Cancer 1991;48:136-41.
21. Cornaglia-Ferraris P, Mariottini GL, Ponzoni M. γ-interferon and retinoic acid synergize in inhibiting the growth of human neuroblastoma cells in nude mice. Cancer Lett 1992;61:215-20.
22. Wada RK, Pai DS, Huang J, Yamashiro JM, Sidell N. Interferon-γ and retinoic acid down-regulate N-myc in neuroblastoma through complementary mechanisms of action. Cancer Lett 1997;121:181-8.
23. Guzhova I, Hultquist A, Cetinkaya C, Nilsson K, Pahlman S, Larsson LG. Interferon-γ cooperates with retinoic acid and phorbol ester to induce differentiation and growth inhibition of human neuroblastoma cells. Int J Cancer 2001;94:97-108.
24. Spinelli W, Sonnenfeld KH, Ishii DN. Effects of phorbol ester tumor promoters and nerve growth factor on neurite outgrowth in cultured human neuroblastoma cells. Cancer Res 1982;42:5067-73.
25. Bahram F, Wu S, Öberg F, Lüscher B, Larsson LG. Posttranslational regulation of Myc function in response to phorbol ester/interferon-γ-induced differentiation of v-Myc-transformed U- 937 monoblasts. Blood 1999;93:3900-12.
26. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of α-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996;13:803-12.
27. Wu S, Pena A, Korcz A, Soprano DR, Soprano KJ. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex. Oncogene 1996;12:621-9.
28. Mac SM, D'Cunha CA, Farnham PJ. Direct recruitment of N-myc to target gene promoters. Mol Carcinog 2000;29:76-86.
29. Gunes C, Lichtsteiner S, Vasserot AP, Englert C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res 2000;60:2116-21.
30. Oh S, Song YH, Yim J, Kim TK. Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene 2000;19:1485-90.
31. Öberg F, Wu S, Bahram F, Nilsson K, Larsson LG. Cytokine-induced restoration of differentiation and cell cycle arrest in v-Myc transformed U-937 monoblasts correlates with reduced Myc activity. Leukemia 2001;15:217-27.
32. Gartel AL, Tyner AL. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 1999;246:280-9.
33. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994;9:3397-406.
34. Steinman RA, Hoffman B, IroA, Guillouf C, Liebermann DA, el-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994;9:3389-96.
35. Borriello A, Pietra VD, Criscuolo M, et al. p27Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation. Oncogene 2000;19:51-60.
36. Nakamura M, Matsuo T, Stauffer J, Neckers L, Thiele CJ. Retinoic acid decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 phosphorylation and an N-myc-independent decrease in Skp2. Cell Death Differ 2003;10:230-9.
37. McArthur GA, Foley KP, Fero ML, et al. MAD1 and p27(KIP1) cooperate to promote terminal differentiation of granulocytes and to inhibit Myc expression and cyclin E-CDK2 activity. Mol Cell Biol 2002;22:3014-23.
38. Walkley CR, Fero ML, Chien WM, Purton LE, McArthur GA. Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells. Nat Cell Biol 2005;7:172-8.
39. Yu JH, Nakajima A, Nakajima H, Diller LR, Bloch KD, Bloch DB. Restoration of promyelocytic leukemia protein-nuclear bodies in neuroblastoma cells enhances retinoic acid responsiveness. Cancer Res 2004;64:928-33.
40. Khan MM, Nomura T, Kim H, et al. Role of PML and PML-RARa in Mad-mediated transcriptional repression. Mol Cell 2001;7:1233-43.
41. Smith KP, Byron M, O'Connell BC, et al. c-Myc localization within the nucleus: evidence for association with the PML nuclear body. J Cell Biochem 2004;93:1282-96.
42. Cairo S, De Falco F, Pizzo M, Salomoni P, Pandolfi PP, Meroni G. PML interacts with Myc, and Myc target gene expression is altered in PML-null fibroblasts. Oncogene 2005;24:2195-203.
43. Miller W, Jr. Differentiation therapy of acute promyelocytic leukemia: clinical and molecular features [see comments]. Cancer Invest 1996;14:142-50.
44. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003;197:185-92.
45. Evans A, Main E, Zier K, et al. The effects of γ interferon on the natural killer and tumor cells of children with neuroblastoma. A preliminary report. Cancer 1989;64:1383-7.
46. Lutz W, Fulda S, Jeremias I, Debatin KM, Schwab M. MycN and IFNγ cooperate in apoptosis of human neuroblastoma cells. Oncogene 1998;17:339-46.
47. Bernassola F, Scheuerpflug C, Herr I, Krammer PH, Debatin KM, Melino G. Induction of apoptosis by IFNγ in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit. Cell Death Differ 1999;6:652-60.
48. Fulda S, Debatin KM. IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 2002;21:2295-308.
49. Yang X, Merchant MS, Romero ME, et al. Induction of caspase 8 by interferon γ renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res 2003;63:1122-9.